Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

Matinas faces imminent NYSE delisting risk after years of losses and shrinking equity.

Risk flags

• ●Delisting risk is acute: The company has received a formal notice of non-compliance from the NYSE American, and is now subject to Section 1009 procedures. Delisting would severely impact liquidity, investor access, and potentially trigger debt covenants or other adverse events.
• ●Persistent multi-year losses: Matinas has reported losses in each of the five most recent fiscal years, indicating a chronic inability to achieve profitability. This pattern raises fundamental questions about the viability of the business model and management’s ability to reverse the trend.
• ●Rapid equity erosion: Stockholders’ equity fell from $4.83 million at year-end 2025 to $3.02 million by March 31, 2026—a $1.81 million decline in just one quarter. Such a steep drop suggests accelerating cash burn or asset impairment, increasing the risk of insolvency.
• ●No disclosed remediation plan: The announcement contains no mention of capital raising, cost-cutting, asset sales, or other measures to restore compliance. The absence of a plan leaves investors with no basis for optimism or recovery.
• ●Limited financial disclosure: Only equity and loss history are provided, with no detail on revenues, cash flows, or operational metrics. This lack of transparency makes it difficult for investors to assess the underlying causes of financial distress or the company’s ability to recover.
• ●Immediate regulatory pressure: The company is now subject to NYSE American’s Section 1009 procedures, which typically impose strict timelines for remediation. Failure to act quickly could result in forced delisting, further eroding shareholder value.
• ●No leadership visibility: There is no commentary from management or identification of responsible executives, which may signal either a lack of strategy or unwillingness to engage with investors during a crisis. This absence undermines confidence in governance and oversight.
• ●All claims are realized, not forward-looking: While this reduces narrative risk, it also means there is no articulated path to improvement—investors are left with only negative facts and no stated plan for change.

Bottom line

For investors, this announcement is a clear warning signal: Matinas BioPharma Holdings, Inc. is at immediate risk of being delisted from the NYSE American due to sustained losses and rapidly declining equity. The company’s financial trajectory is negative, with equity dropping by $1.81 million in a single quarter and no sign of profitability over five years. There is no evidence of a turnaround plan, capital infusion, or operational improvement—only a factual admission of non-compliance. The lack of management commentary or remedial disclosure leaves investors in the dark about any potential for recovery. No notable institutional figures or insiders are referenced, so there is no external validation or implied support. To change this assessment, the company would need to disclose a credible, fully funded remediation plan—such as a binding capital raise, cost restructuring, or strategic partnership—along with detailed financials showing a path to compliance. In the next reporting period, investors should watch for any updates on remediation efforts, changes in equity, or further regulatory actions. Given the immediacy and severity of the risks, this is not a signal to buy or hold, but rather a situation to monitor closely or avoid until there is clear evidence of stabilization. The single most important takeaway: without swift, concrete action, Matinas faces a high probability of delisting and further value destruction.

Announcement summary

(NYSE:MTNB) Matinas BioPharma Holdings, Inc. announced that on June 24, 2026, it received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. The Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.

Disagree with this article?